PMID: 16518132Mar 7, 2006Paper

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia

Clinical Neuropharmacology
Fayçal MouaffakDavid Gourion

Abstract

Approximately 40% to 70% of neuroleptic-resistant schizophrenic patients are nonresponders to clozapine. Several clozapine augmentation strategies have come into clinical practice although often without evidence-based support. Among these strategies, the combined use of clozapine with another antipsychotic has been reported for up to 35% of patients receiving clozapine. The purposes of the present work were to (1) review the available literature on the efficacy and safety of the clozapine augmentation with another antipsychotic using a MEDLINE search of the literature from 1978 to December 2005 and (2) to propose an operational definition of schizophrenia refractory to clozapine ("ultraresistant schizophrenia") for the implementation and homogenization of future therapeutic trials. Case controls and open clinical trials largely dominate the literature, and there are only 4 double-blind studies of clozapine augmentation with antipsychotics. The results of these studies are somewhat discrepant. Moreover, the heterogeneity of definitions of resistance to clozapine, of outcome measures and of dose and duration of pharmacological trials is a major limitation for drawing conclusions.

References

Jan 1, 1991·Schizophrenia Bulletin·G W ChristisonR J Wyatt
Jan 1, 1990·Schizophrenia Bulletin·H D BrennerK K Midha
Jan 1, 1989·Psychopharmacology·W Z PotterW W Yan
Mar 1, 1995·Pharmacopsychiatry·R H McCarthy, K G Terkelsen
Nov 1, 1995·American Journal of Respiratory and Critical Care Medicine·C ShindohK Shirato
Jun 1, 1996·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·S A ChongH S Lee
Dec 1, 1996·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·S Mowerman, S G Siris
Dec 16, 1997·The American Journal of Psychiatry·J K PatelM T Tsuang
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·R ShilohA Weizman
May 1, 1999·Acta Psychiatrica Scandinavica·A L MoreraJ L Cano-Muñoz
Jul 6, 2000·The Australian and New Zealand Journal of Psychiatry·A Adesanya, C Pantelis
Jul 8, 2000·Schizophrenia Bulletin·S A Chong, G Remington
Apr 1, 1997·Journal of Clinical Psychopharmacology·S A ChongH S Lee
Oct 13, 2000·The Journal of Clinical Psychiatry·E Rhoads
Dec 1, 2000·Acta Psychiatrica Scandinavica·J H StubbsC Q Mountjoy
Mar 15, 2001·The Journal of Clinical Psychiatry·I W de GrootP N van Harten
May 11, 2001·Schizophrenia Research·C G TaylorW G Honer
Jan 31, 2002·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vassilis P KontaxakisGeorge N Christodoulou
Feb 5, 2002·Schizophrenia Bulletin·P BuckleyJ Csernansky
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michele FabrazzoMario Maj
Dec 26, 2002·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Marie-Andrée BeaucheminKhoa Anh Nguyen
Dec 31, 2002·Schizophrenia Research·Rajaprabhakaran RajarethinamJohn DeQuardo
Mar 14, 2003·The Journal of Clinical Psychiatry·Junji Takeshita
Mar 14, 2003·The Journal of Clinical Psychiatry·Neil S Kaye
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Vladimir LernerRael D Strous
Mar 26, 2004·Der Nervenarzt·R RupprechtH-J Möller
May 4, 2004·The American Journal of Psychiatry·Marcus W AgelinkIsmail Ak
May 4, 2004·The American Journal of Psychiatry·David Israeli, Joseph Zohar
Sep 16, 2004·The Journal of Clinical Psychiatry·Sabina LimChandra Cooper
Dec 31, 2004·The American Journal of Psychiatry·Richard C JosiassenRita A Shaughnessy
May 13, 2005·Schizophrenia Bulletin·Joselyn L SellenNicola S Gray
Jan 1, 1997·European Psychiatry : the Journal of the Association of European Psychiatrists·R ShilohA Weizman

❮ Previous
Next ❯

Citations

Apr 1, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Lone BaandrupBirte Glenthoj
Sep 21, 2013·Schizophrenia Bulletin·Saeed FarooqGary Remington
May 10, 2011·Neuropsychiatric Disease and Treatment·Meghan E McIlwainBruce R Russell
Feb 22, 2011·Pharmacogenomics·Fayçal MouaffakMarie Odile Krebs
Oct 1, 2007·Indian Journal of Psychiatry·Ram K SolankiMukesh K Swami
Jan 6, 2010·Indian Journal of Psychiatry·R K SolankiDeepti Munshi
Jul 10, 2014·ISRN Psychiatry·Natalia BartolommeiLorenzo Lattanzi
Jan 7, 2015·Pharmacology & Therapeutics·Sonali ReisingerDaniela D Pollak
Mar 24, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Roland M DardennesFrédéric Rouillon
Aug 12, 2009·Progress in Neuro-psychopharmacology & Biological Psychiatry·Dellagi LamiaTabbane Karim
Aug 28, 2007·The Psychiatric Clinics of North America·Helio Elkis
Nov 10, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Charalampos I MitsonisMaria Nefeli E Katsanou
Oct 10, 2013·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Paul A Tiffin, Patrick Welsh
May 25, 2016·The Psychiatric Clinics of North America·Helio Elkis, Peter F Buckley
Oct 7, 2014·Expert Opinion on Pharmacotherapy·Maria Rosaria A MuscatelloRocco Zoccali
Jan 22, 2015·The International Journal of Neuropsychopharmacology·Meghan Elizabeth GoldsteinBruce R Russell
Feb 27, 2015·The International Journal of Neuropsychopharmacology·Valerie M AndersonBruce R Russell
Nov 12, 2013·Schizophrenia Research·Gary RemingtonMargaret Hahn
May 22, 2016·Expert Opinion on Drug Safety·G RemingtonV Powell
Mar 1, 2008·Journal of Psychopharmacology·G C-L Hung, Y-Y Chen
Oct 20, 2006·Journal of Psychopharmacology·Kanapathippillai KarunakaranGiles C Harborne
Jul 14, 2017·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Gary RemingtonMichael Teehan
Aug 11, 2007·International Clinical Psychopharmacology·A Carlo AltamuraHerbert Y Meltzer
Dec 22, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Constantin TranulisEmmanuel Stip
Dec 25, 2009·CNS Drugs·Gary RemingtonOfer Agid
Dec 30, 2014·Frontiers in Psychiatry·Pascal SienaertGábor Gazdag
Oct 14, 2017·Journal of Clinical Psychopharmacology·Robert J FeeleyGihyun Yoon
Apr 8, 2011·Expert Review of Neurotherapeutics·Gary RemingtonGeorge Foussias
Aug 28, 2019·Pharmacogenomics·Estela SangüesaCristina Belén García
Mar 3, 2011·Journal of Clinical Psychopharmacology·Fayçal MouaffakAmine Benyamina
Jan 1, 2016·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Jimmy LeeGary Remington
Jan 11, 2013·Clinical Schizophrenia & Related Psychoses·Margaret K HahnGary Remington
Jul 26, 2021·Journal of Psychiatric Research·Marco SpangaroRoberto Cavallaro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here